SCHEMBL4495280

SCHEMBL4495280

COCCCNc1nc2cc(OC)ccc2cc1C(=O)O

nearest known ligand 0.48

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.48
MEN1 O00255 3/20 0.48
SLC16A3 O15427 1/20 0.44
KDM4E B2RXH2 6/20 0.44
ALDH1A1 P00352 6/20 0.44
POLB P06746 6/20 0.43
HPGDS O60760 5/20 0.43
HPGD P15428 3/20 0.42
BRD4 O60885 2/20 0.42
HSD17B10 Q99714 1/20 0.42
NPC1 O15118 4/20 0.42
RAB9A P51151 4/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
GLA P06280 2/20 0.42
GAA P10253 2/20 0.42
RECQL P46063 1/20 0.42
TDP1 Q9NUW8 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4478082 0.94 MEN1 (0.52) KMT2AMEN1SLC16A3KDM4EALDH1A1
SCHEMBL4489575 0.89 MERTK (0.47) KMT2AMEN1SLC16A3KDM4EALDH1A1
SCHEMBL4493667 0.88 SYK (0.46) KMT2AMEN1SLC16A3KDM4EALDH1A1
SCHEMBL4495043 0.88 SLC16A3 (0.46) KMT2AMEN1SLC16A3KDM4EALDH1A1
SCHEMBL4487682 0.88 ALDH1A1 (0.49) KMT2AMEN1SLC16A3KDM4EALDH1A1
SCHEMBL4487199 0.87 BRD4 (0.45) KMT2AMEN1SLC16A3KDM4EALDH1A1
SCHEMBL4489484 0.87 TDP1 (0.50) KMT2AMEN1SLC16A3KDM4EALDH1A1
SCHEMBL4481447 0.87 FERMT2 (0.45) KMT2AMEN1SLC16A3KDM4EALDH1A1
SCHEMBL4491458 0.86 TERT (0.50) KMT2AMEN1KDM4EALDH1A1POLB
SCHEMBL4498604 0.85 NUDT1 (0.46) KMT2AMEN1SLC16A3KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7482455-B2 Chemical compounds SMITHKLINE BEECHAM CORPORATION (US) 2009-01-27 US claimed
EP-1556379-A4 CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORP (US) 2007-06-13 EP claimed
US-20060106058-A1 Chemical compounds BURGESS JOELLE L 2006-05-18 US claimed
EP-1556379-A2 CHEMICAL COMPOUNDS SmithKline Beecham Corporation (US) 2005-07-27 EP claimed
WO-2004034985-A2 CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2004-04-29 WO claimed
US-7482455-B2 Chemical compounds SMITHKLINE BEECHAM CORPORATION (US) 2009-01-27 US disclosed
EP-1556379-A4 CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORP (US) 2007-06-13 EP disclosed
US-20060106058-A1 Chemical compounds BURGESS JOELLE L 2006-05-18 US disclosed
EP-1556379-A2 CHEMICAL COMPOUNDS SmithKline Beecham Corporation (US) 2005-07-27 EP disclosed
WO-2004034985-A2 CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2004-04-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060106058-A1 Chemical compounds YARS1, DAPK3, NEK3 KMT2A 3192/4885MEN1 2541/4885SLC16A3 3091/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.